Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Cure to Lung Cancer May Depend on Your DNA

August 7, 2014 1:00 pm | News | Comments

The Northside Hospital Cancer Institute announced its participation in a unique National Cancer Institute clinical collaboration to treat lung cancer based on a person’s genetic makeup. Read more...               

TOPICS:

FDA Approves Orbactiv to Treat Skin Infections

August 7, 2014 1:00 pm | News | Comments

The FDA approved Orbactiv (oritavancin), a new antibacterial drug to treat adults with skin infections, including Staphylococcus aureus, various Streptococcus species and Enterococcus faecalis. Read more...         

TOPICS:

Ethical Issue: Who Gets Experimental Ebola Drug?

August 7, 2014 1:00 pm | News | Comments

The use of an experimental drug to treat two Americans diagnosed with Ebola is raising ethical questions about who gets first access to unproven new therapies for the deadly disease. Read more...                

TOPICS:
Advertisement

Mylan Profit Drops 30% in Q2

August 7, 2014 1:00 pm | News | Comments

Mylan Inc. on Thursday reported profit that declined by 30 percent in its second quarter, and missed analysts' expectations. The Canonsburg, Pennsylvania-based company said net income fell to $125.2 million. Read more...       

TOPICS:

Takeda to Extend Global Reach

August 7, 2014 1:00 pm | News | Comments

New Takeda Pharmaceutical Co. President Christophe Weber said recently that Japan's biggest drugmaker will continue efforts to expand its business abroad through acquisitions and will outline a new strategy by the end of the year. Read more...  

TOPICS:

Study Correlates Immune Response, Improved Survival in Prostate Cancer

August 7, 2014 10:58 am | News | Comments

Generex Biotechnology Corp. announced publication of a follow-up study from a Phase 1 clinical trial of the immunotherapeutic agent AE37 in patients with prostate cancer that demonstrates an association between a specific immune response generated by AE37 and improved overall survival. Read more...

TOPICS:

Last Patient Completes Oramed Oral Insulin Trial

August 7, 2014 10:52 am | News | Comments

Oramed Pharmaceuticals Inc. reported that the last patient has completed treatment in its Phase 2a clinical trial of ORMD-0801, the company's proprietary oral insulin capsule, to treat type 1 diabetes, and top-line data is expected to be reported in the fourth quarter of 2014. Read more...

TOPICS:

Daiichi Sankyo, Charleston Labs Collaborate on Pain Meds

August 7, 2014 10:47 am | News | Comments

Daiichi Sankyo and Charleston Laboratories Inc. announced that the parties have entered into a strategic collaboration for the development and U.S. commercialization of novel hydrocodone combination products, including CL-108, being studied for the treatment of acute pain as well as the reduction of Opioid-Induced Nausea and Vomiting. Read more...

TOPICS:
Advertisement

Health Canada Approves Abraxane, Gemcitabine for Pancreatic Cancer

August 7, 2014 10:39 am | News | Comments

Health Canada has approved Abraxane for Injectable Suspension (paclitaxel powder for injectable suspension) (nanoparticle, albumin-bound [nab] paclitaxel) for first-line treatment of adult patients with metastatic pancreatic cancer. Read more...

TOPICS:

Pfizer to Pay $35M to Settle Unapproved Use Case

August 7, 2014 10:34 am | News | Comments

Pfizer will pay $35 million to resolve allegations by 42 states that its subsidiary, Wyeth Pharmaceuticals, illegally marketed an organ transplant drug for unapproved uses, but did not admit any wrongdoing or liability as part of the settlement. Read more...

TOPICS:

Ebola Vaccine Antibodies Are Made in Tobacco Plants

August 7, 2014 10:27 am | News | Comments

Charlie Arntzen has worked tirelessly on new platforms to deliver drugs and focused on plant-based drug delivery systems, testing a wide range of plants as possible “manufacturing platforms” for therapeutics for the developing world. Read more...

TOPICS:

BDSI Reports 'Encouraging' Results from Phase 3 Analysis

August 6, 2014 3:31 pm | News | Comments

BioDelivery Sciences International Inc. announced that it has completed a pre-specified interim analysis of the ongoing initial pivotal Phase 3 trial for Clonidine Topical Gel for the treatment of painful diabetic neuropathy (PDN). Read more...  

TOPICS:

Cubist Recalls Some Cubicin Lots

August 6, 2014 3:25 pm | News | Comments

Cubist announced it is voluntarily recalling certain lots of Cubicin (daptomycin for injection) to the user level due to the potential presence of glass particulate matter in vials produced by a contract manufacturer. Read more...       

TOPICS:

Year-round Preventive Meds Reduce Malaria Risk in Young Children

August 6, 2014 3:20 pm | News | Comments

A year-round preventive drug treatment substantially reduces young children’s risk of contracting malaria and poses no serious risk of adverse events, according to a study. Read more...                   

TOPICS:

Aspirin Cuts Risk of Digestive Tract Cancers

August 6, 2014 3:07 pm | News | Comments

New research reveals that taking aspirin can significantly reduce the risk of developing– and dying from– the major cancers of the digestive tract, i.e. bowel, stomach and esophageal cancer. Read more...              

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading